European Pharmaceutical Review
NOVEMBER 6, 2023
million in 2023, with a predicted compound annual growth rate (CAGR) of 4.1 Demand for cell lines “in drug development , vaccine production, and therapeutic research is surging”, setting the market up for significant expansion, Ghosh noted. Total cell line product sales are expected to reach $3,124.4
Safe Biologics
JUNE 12, 2023
Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
APRIL 3, 2024
As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 This is due to these companies looking to meet to the varied needs of pharmaceutical developers, according to the authors. This is contributing to a more streamlined and efficient approach to drug development, according to the report.
Safe Biologics
JUNE 12, 2023
Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).
Express Pharma
JUNE 5, 2023
GlobalData’s latest report, ‘Myelofibrosis: Eight-Market Drug Forecast and Market Analysis,’ reveals that the MF market will grow from $2.39 billion in 2031 across the 8MM, registering a compound annual growth rate (CAGR) of 1.9 billion in 2021 to $2.89 per cent, driven by the approvals of nine pipeline agents.
Pharmaceutical Technology
SEPTEMBER 13, 2022
Together, these strategies are anticipated to boost development processes from pre-clinical to first-in-human clinical trials with quicker transition times. In August, the company announced plans to spin off Sandoz, its generics and biosimilars division , to create a new standalone company.
Pharmaceutical Technology
DECEMBER 9, 2022
Research and development highlights from the research period include the company’s work with Mirati Therapeutics in developing methods to determine torsion rotational energy barriers of the clinical compound, MRTX1719, which is being developed for use as an inhibiter to MTAP-deleted cancers. HQ ADDRESS: Römerpark 2.
Expert insights. Personalized for you.
83 
Let's personalize your content